FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290803731> ?p ?o ?g. }

• W4290803731 endingPage "928" @default.
• W4290803731 startingPage "914" @default.
• W4290803731 abstract "Wnt signaling is implicated in the etiology of gastrointestinal tract cancers. Targeting Wnt signaling is challenging due to on-target toxicity concerns and lack of druggable pathway components. We describe the discovery and characterization of RXC004, a potent and selective inhibitor of the membrane-bound o-acyl transferase Porcupine, essential for Wnt ligand secretion. Absorption, distribution, metabolism, and excretion and safety pharmacology studies were conducted with RXC004 in vitro, and pharmacokinetic exposure assessed in vivo. RXC004 effects on proliferation and tumor metabolism were explored in genetically defined colorectal and pancreatic cancer models in vitro and in vivo. RXC004 effects on immune evasion were assessed in B16F10 immune cold and CT26 immune hot murine syngeneic models, and in human cell cocultures. RXC004 showed a promising pharmacokinetic profile, inhibited Wnt ligand palmitoylation, secretion, and pathway activation, and demonstrated potent antiproliferative effects in Wnt ligand-dependent (RNF43-mutant or RSPO3-fusion) colorectal and pancreatic cell lines. Reduced tumor growth and increased cancer cell differentiation were observed in SNU-1411 (RSPO3-fusion), AsPC1 and HPAF-II (both RNF43-mutant) xenograft models, with a therapeutic window versus Wnt homeostatic functions. Additional effects of RXC004 on tumor cell metabolism were confirmed in vitro and in vivo by glucose uptake and 18fluorodeoxyglucose-PET, respectively. RXC004 stimulated host tumor immunity; reducing resident myeloid-derived suppressor cells within B16F10 tumors and synergizing with anti-programmed cell death protein-1 (PD-1) to increase CD8+/regulatory T cell ratios within CT26 tumors. Moreover, RXC004 reversed the immunosuppressive effects of HPAF-II cells cocultured with human peripheral blood mononuclear cells, confirming the multiple anticancer mechanisms of this compound, which has progressed into phase II clinical trials.Wnt pathway dysregulation drives many gastrointestinal cancers; however, there are no approved therapies that target the pathway. RXC004 has demonstrated the potential to block both tumor growth and tumor immune evasion in a genetically defined, clinically actionable subpopulation of Wnt ligand-dependent gastrointestinal cancers. The clinical utility of RXC004, and other Porcupine inhibitors, in such Wnt ligand-dependent cancers is currently being assessed in patient trials." @default.
• W4290803731 created "2022-08-12" @default.
• W4290803731 creator A5003246050 @default.
• W4290803731 creator A5013808307 @default.
• W4290803731 creator A5045023434 @default.
• W4290803731 creator A5055499083 @default.
• W4290803731 creator A5060597851 @default.
• W4290803731 creator A5063198530 @default.
• W4290803731 creator A5066339819 @default.
• W4290803731 creator A5067029431 @default.
• W4290803731 creator A5081842675 @default.
• W4290803731 creator A5082399428 @default.
• W4290803731 creator A5091755518 @default.
• W4290803731 date "2022-09-02" @default.
• W4290803731 modified "2023-10-14" @default.
• W4290803731 title "The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models" @default.
• W4290803731 cites W1586218645 @default.
• W4290803731 cites W1655178001 @default.
• W4290803731 cites W1900557155 @default.
• W4290803731 cites W1994029539 @default.
• W4290803731 cites W1995773697 @default.
• W4290803731 cites W2006419043 @default.
• W4290803731 cites W2017828716 @default.
• W4290803731 cites W2022495797 @default.
• W4290803731 cites W2031868265 @default.
• W4290803731 cites W2041812469 @default.
• W4290803731 cites W2063188304 @default.
• W4290803731 cites W2063495860 @default.
• W4290803731 cites W2067826589 @default.
• W4290803731 cites W2078060536 @default.
• W4290803731 cites W2083457841 @default.
• W4290803731 cites W2090789702 @default.
• W4290803731 cites W2106541980 @default.
• W4290803731 cites W2132659357 @default.
• W4290803731 cites W2135372466 @default.
• W4290803731 cites W2142300779 @default.
• W4290803731 cites W2157216791 @default.
• W4290803731 cites W2165087323 @default.
• W4290803731 cites W2166178545 @default.
• W4290803731 cites W2168623286 @default.
• W4290803731 cites W2207864075 @default.
• W4290803731 cites W2308877979 @default.
• W4290803731 cites W2558715006 @default.
• W4290803731 cites W2655262992 @default.
• W4290803731 cites W2748338775 @default.
• W4290803731 cites W2756896022 @default.
• W4290803731 cites W2771031544 @default.
• W4290803731 cites W2783494975 @default.
• W4290803731 cites W2801923172 @default.
• W4290803731 cites W2803586435 @default.
• W4290803731 cites W2886229758 @default.
• W4290803731 cites W2888597034 @default.
• W4290803731 cites W2891828924 @default.
• W4290803731 cites W2894924427 @default.
• W4290803731 cites W2909312563 @default.
• W4290803731 cites W2952001837 @default.
• W4290803731 cites W2976026968 @default.
• W4290803731 cites W3088005314 @default.
• W4290803731 cites W3100750497 @default.
• W4290803731 cites W3106403851 @default.
• W4290803731 cites W3158215128 @default.
• W4290803731 cites W3159588552 @default.
• W4290803731 cites W4221016108 @default.
• W4290803731 cites W808646684 @default.
• W4290803731 doi "https://doi.org/10.1158/2767-9764.crc-21-0095" @default.
• W4290803731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36922934" @default.
• W4290803731 hasPublicationYear "2022" @default.
• W4290803731 type Work @default.
• W4290803731 citedByCount "2" @default.
• W4290803731 countsByYear W42908037312023 @default.
• W4290803731 crossrefType "journal-article" @default.
• W4290803731 hasAuthorship W4290803731A5003246050 @default.
• W4290803731 hasAuthorship W4290803731A5013808307 @default.
• W4290803731 hasAuthorship W4290803731A5045023434 @default.
• W4290803731 hasAuthorship W4290803731A5055499083 @default.
• W4290803731 hasAuthorship W4290803731A5060597851 @default.
• W4290803731 hasAuthorship W4290803731A5063198530 @default.
• W4290803731 hasAuthorship W4290803731A5066339819 @default.
• W4290803731 hasAuthorship W4290803731A5067029431 @default.
• W4290803731 hasAuthorship W4290803731A5081842675 @default.
• W4290803731 hasAuthorship W4290803731A5082399428 @default.
• W4290803731 hasAuthorship W4290803731A5091755518 @default.
• W4290803731 hasBestOaLocation W42908037311 @default.
• W4290803731 hasConcept C137620995 @default.
• W4290803731 hasConcept C150903083 @default.
• W4290803731 hasConcept C203014093 @default.
• W4290803731 hasConcept C207001950 @default.
• W4290803731 hasConcept C502942594 @default.
• W4290803731 hasConcept C62478195 @default.
• W4290803731 hasConcept C86803240 @default.
• W4290803731 hasConcept C8891405 @default.
• W4290803731 hasConcept C95444343 @default.
• W4290803731 hasConcept C98274493 @default.
• W4290803731 hasConceptScore W4290803731C137620995 @default.
• W4290803731 hasConceptScore W4290803731C150903083 @default.
• W4290803731 hasConceptScore W4290803731C203014093 @default.
• W4290803731 hasConceptScore W4290803731C207001950 @default.
• W4290803731 hasConceptScore W4290803731C502942594 @default.

• next